BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Carbidopa

An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.

298+ PubMed studies analyzed · 56 RCTs · Evidence Score: 52.8

Research Domains

Carbidopa has been studied across 15 research domains including 🧠 Neuroprotection, 🦠 Gut & Microbiome, 🌤️ Mood & Depression, 🧠 Focus & Attention, ✨ Skin & Hair. The primary research focus is 🧠 Neuroprotection with 65% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Carbidopa, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Carmine
4 shared targets
Kynurenic
3 shared targets
Dihydroxyphenylalanine
3 shared targets
Inositol
2 shared targets
Chlorophyll
2 shared targets
Picloram
2 shared targets
Diamide
2 shared targets
Sulfinpyrazone
3 shared targets
Nialamide
2 shared targets
6-Aminonicotinamide
2 shared targets
Loading evidence profile...

This evidence profile for Carbidopa is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.